Herbal administration and interaction of cancer treatment

Journal of Palliative Medicine

Volumn 16, Issue 11, 2013, Pages 1466-1476

  Arslan, Deniz ^a   Tural, Deniz ^b   Akar, Emre ^b  

^a AKDENIZ UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DACARBAZINE; DOCETAXEL; DOXORUBICIN; DRUG METABOLITE; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; HERBACEOUS AGENT; IRINOTECAN; KAVA; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TAXANE DERIVATIVE; TENIPOSIDE; UNINDEXED DRUG; VALERIAN; VINBLASTINE; VINCRISTINE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLERGIC REACTION; ALLERGIC RHINITIS; ALLERGY; ALTERNATIVE MEDICINE; ANAPHYLAXIS; ARTERITIS; ARTHRITIS; ASTHENIA; ASTRAGALUS PLANT; AWARENESS; BILBERRY; BLEEDING; BLUEBERRY; BRONCHITIS; CANCER PATIENT; CANCER PREVENTION; CANCER THERAPY; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHINESE MEDICINE; CHRONIC HEPATITIS; CLINICAL TRIAL (TOPIC); CONFUSION; CONSTIPATION; CURCUMA; DEPRESSION; DIABETES MELLITUS; DIABETIC RETINOPATHY; DIARRHEA; DIGITALIS INTOXICATION; DIZZINESS; DOCTOR PATIENT RELATION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG INDICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; ECHINACEA; EMBOLISM; EUPHORIA; EVENING PRIMROSE; FATTY LIVER; FEVER; GALACTORRHEA; GANODERMA LUCIDUM; GARLIC; GASTROINTESTINAL DISEASE; GINGER; GINKGO BILOBA; GINSENG; GLYCYRRHIZA; GYNECOMASTIA; HEADACHE; HEART DISEASE; HEART FAILURE; HERBAL MEDICINE; HORSERADISH; HOT FLUSH; HUCKLEBERRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERICUM PERFORATUM; HYPERLIPIDEMIA; HYPERSENSITIVITY; HYPERTENSION; HYPOGLYCEMIA; HYPOKALEMIA; HYPOTENSION; HYPOTHERMIA; INSOMNIA; LIBIDO DISORDER; LIVER CIRRHOSIS; LIVER TOXICITY; LUNG CANCER; LUNG EDEMA; MASTALGIA; MENOPAUSAL SYNDROME; METEORISM; MUSCLE CRAMP; MYOPATHY; NAIL COLOR DEFECT; NAUSEA; NEOPLASM; NEPHRITIS; NERIUM OLEANDER; NEUROPATHY; OSTEOPOROSIS; PAIN; PARALYSIS; PLANT SEED; PREGNANCY COMPLICATION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PSORIASIS; RED GRAPE SEED; RESPIRATORY TRACT DISEASE; RESTLESSNESS; REVIEW; RHEUMATOID ARTHRITIS; SABAL; SCLERODERMA; SIDE EFFECT; SILYBUM MARIANUM; SKIN ALLERGY; SKIN DISCOLORATION; SLEEP DISORDER; SOYBEAN; STOMACH DISEASE; STOMACH IRRITATION; STOMACH ULCER; STUPOR; TEA; THROMBUS; URINARY TRACT INFECTION; URTICA DIOICA; VAGINA BLEEDING; VISCUM ALBUM; VISUAL DISORDER; VOMITING; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; HUMANS; NEOPLASMS; PALLIATIVE CARE; PHYTOTHERAPY;

EID: 84887913510     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2013.0126     Document Type: Review

References (140)

1. Qi F, Li A, Inagaki Y, Gao J, Li J, Kokudo N, et al.: Chinese herbal medicines as adjuvant treatment during chemo-or radio-therapy for cancer. BioScience Trends 2010;4:297-307.
2. Cxelik S, Konkan R, Erkmen H, Tabo A, Erk?ran M: Herbal medicine and their use in psychiatry. Düsxünen Adam 2007;20:186-195.
3. Gansler T, Kaw C, Crammer C, Smith T: A populationbased study of prevalence of complementary methods use by cancer survivors: A report from the American Cancer Society's studies of cancer survivors. Cancer 2008;113:1048-1057.
4. Kav S, Hanoǧlu Z, Alg?er L: Use of complementary and alternative medicine by cancer patients in Turkey: A literature review. UHOD 2008;18:32-38.
5. Deng GE, Frenkel M, Cohen L, Cassileth BR, Abrams DI, Capodice JL, et al.: Evidence-based clinical practice guidelines for ?ntegrative oncology: Complementary therapies and botanicals. J Soc Integr Oncol 2009;7:85-120.
6. Ades T, Yarbro HC: Alternative and complementary therapies in cancer management. In: Yarbro HC, Frogge MH, Goodman M (eds): Cancer Nursing Principles and Practice, 5th ed. 2000, pp. 617-628.
7. Kemper KJ, Vohra S, Walls R: The use of complementary and alternative medicine in pediatrics. Pediatrics 2008;122:1374-1386.
8. Konrad L, Müller HH, Lenz C, Laubinger H, Aumüller G, Lichius JJ: Antiproliferative effect on human prostate cancer cells by a stinging nettle root (Urtica dioica) extract. Planta Med 2000;66:44-47.
9. Safarinejad MR: Urtica dioica for treatment of benign prostatic hyperplasia: A prospective, andomized, doubleblind, placebo-controlled, crossover study. J Herb Pharmacother 2005;5:1-11.
10. Ozkol H, Musa D, Tuluce Y, Koyuncu I: Ameliorative influence of Urtica dioica L against Cisplatin induced toxicity in mice bearing Ehrlich ascites carcinoma. Drug Chem Toxicol 2012;35:251-257
11. Tasaki K, Maskarinec G, Shumay DM, Tatsumura Y, Kakai H: Communication between physicians and cancer patients about complementary and alternativemedicine: Exploring patients' perspectives. Psychooncology 2002;11:212-220.
12. Urtica dioica; Urtica urens (nettle). Altern Med Rev 2007;12:280-284.
13. Ozen TK: Modulatory effect of Urtica dioica L. (Urticaceae) leaf extract on biotransformation enzyme systems, antioxidant enzymes, lactate dehydrogenase and lipid peroxidation in mice. Phytomedicine 2003;1:405-415.
14. Tahri A, Yamani S, Legssyer A, Aziz M, Mekhfi H, Bnouham M, et al.: Acute diuretic, natriuretic and hypotensive effects of a continuous perfusion of aqueous extract of Urtica dioica in the rat. J Ethnopharmacol 2000;73:95-100.
15. Asxc? A, Baydar T, Sxahin G: Evaluation of usage of herbal preparation and drug interactions in elderly people from toxicological aspect. Turkish J Geriatr 2007;10: 203-14.
16. Izzo AA: Interactions between herbs and conventional drugs: Overview of the clinical data. Med Princ Pract 2012;21:404-428.
17. Sparreboom A, Cox MC, Acharya MR, Figg WD: Herbal remedies in the United States: Potential adverse interactions with anticancer agents. J Clin Oncol 2004;22:2489-2503.
18. Markman M: Safety issues in using complementary and alternative medicine. J Clin Oncol 2002;20(S18):S39-S41.
19. Ang-Lee MK, Moss J, Yuan CS: Herbal Medicines and perioperative care. JAMA 2001;286:208-216.
20. Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J: The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002;34:234-238.
21. Madkor HR, Mansour SW, Ramadan G: Modulatory effects of garlic, ginger, turmeric and their mixture on hyperglycaemia, dyslipidaemia and oxidative stress in streptozotocin-nicotinamide diabetic rats. Br J Nutr 2011;105:1210-1217.
22. Jian L, Xie LP, Lee AH, Binns CW: Protective effect of green tea against prostate cancer: A case control study in southeast China. Int J Cancer 2004;108:130-135.
23. Kikuchi N, Ohmori K, Shimazu T, Nakaya N, Kuriyama S, Nishino Y, et al.: No association between green tea and prostate cancer risk in Japanese men: The Ohsaki Cohort Study. Br J Cancer 2006;95:371-373.
24. Severson RK, Nomura AM, Grove JS, Stemmermann GN: A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res 1989;49:1857-1860.
25. Sonoda T, Nagata Y, Mori M, Miyanaga N, Takashima N, Okumura K, et al.: A case-control study of diet and prostate cancer in Japan: Possible protective effect of traditional Japanese diet. Cancer Sci 2004;95:238-242.
26. Laurie SA, Miller VA, Grant SC, Kris MG, Ng KK: Phase I study of green tea extract in patients with advanced lung cancer. Cancer Chemother Pharmacol 2005;55:33-38.
27. Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, et al.: A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003;97:1442-1446.
28. Dy GK, Bekele L, Hanson LJ, Furth A, Mandrekar S, Sloan JA, et al.: Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. J Clin Oncol 2004;22:4810-4815.
29. Golden EB, Lam PY, Kardosh A, Gaffney KJ, Cadenas E, Louie SG, et al.: Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 2009;113:5927-5937.
30. Shu XO, Jin F, Dai Q, Wen W, Potter JD, Kushi LH, et al.: Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiol Biomarkers Prev 2001;10:483-488.
31. Wu AH, Wan P, Hankin J, Tseng CC, Yu MC, Pike MC: Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis 2002;23:1491-1496.
32. Korde LA, Wu AH, Fears T, Nomura AM, West DW, Kolonel LN, et al.: Childhood soy intake and breast cancer risk in Asian American women. Cancer Epidemiol Biomarkers Prev 2009;18:1050-1059.
33. Fagelman E, Lowe FC. Herbal medications in the treatment of benign prostatic hyperplasia (BPH). Urol Clin N Am 2002;29:23-29.
34. Gerber GS, Zagaja GP, Bales GT, Chodak GW, Contreras BA: Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: Effects on urodynamic parameters and voiding symptoms. Urology 1998;51:1003-1007.
35. Boyle P, Robertson C, Lowe F, Roehrborn C: Meta-analysis of clinical trials of permixon (saw palmetto) in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000;55:533-539.
36. Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C: Saw palmetto extracts for treatment of benign prostatic hyperplasia: A systematic review. JAMA 1998;280:1604-1609.
37. Attele AS, Wu JA, Yuan CS: Ginseng pharmacology: Multiple constituents and multiple actions. Biochem Pharmacol 1999;58:1685-1693.
38. Cui Y, Shu XO, Gao YT, Cai H, Tao MH, Zheng W: Association of ginseng use with survival and quality of life among breast cancer patients. Am J Epidemiol 2006;163:645-653.
39. Cho YK, Sung H, Lee HJ, Joo CH, Cho GJ: Longterm intake of Korean red ginseng in HIV-1-infected patients: Development of resistance mutation to zidovudine is delayed. Int Immunopharmacol 2001;1:1295-1305.
40. Scaglione F, Cattaneo G, Alessandria M, Cogo R: Efficacy and safety of the standardized ginseng extract G115 for potentiating vaccination against common cold and-or influenza syndrome. Drugs Exp Clin Res 1996;22:65-72.
41. Lee Y, Jin Y, Lim W, Ji S, Choi S, Jang S, et al.: A ginsenoside-Rh1, a component of ginseng saponin, activates estrogen receptor in human breast carcinoma MCF-7 cells. J Steroid Biochem Mol Biol 2003;84:463-468.
42. Delaey E, Vandenbogaerde A, Merlevede W, de Witte P: Photocytotoxicity of hypericin in normoxic and hypoxic conditions. J Photochem Photobiol B 2000;56:19-24.
43. Chen B, de Witte PA: Photodynamic therapy efficacy and tissue distribution of hypericin in a Mouse P388 lymphoma tumor model. Cancer Lett 2000;150:111-117.
44. Kamuhabwa AR, Agostinis P, D'Hallewin MA, Kasran A, de Witte PA: Photodynamic activity of hypericin in human urinary bladder carcinoma cells. Anticancer Res 2000;20: 2579-2584.
45. Liu CD, Kwan D, Saxton RE, McFadden DW: Hypericin and photodynamic therapy decreases human pancreatic cancer in vitro and in vivo. J Surg Res 2000;93:137-143.
46. Colasanti A, Kisslinger A, Liuzzi R, Quarto M, Riccio P, Roberti G, et al.: Hypericin photosensitization of tumor and metastatic cell lines of human prostate. J Photochem Photobiol B 2000;54:103-107.
47. Alecu M, Ursaciuc C, Halalau F, Coman G, Merlevede W, Waelkens E, et al.: Photodynamic treatment of basal cell carcinoma and squamous cell carcinoma with hypericin. Anticancer Res 1998;18:4651-4654.
48. Wuttke W, Gorkow C, Seidlova-Wuttke D: Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: A doubleblind, placebo-controlled, and conjugated estrogens-controlled study. Menopause 2006;13:185-196.
49. Chan BY, Lau KS, Jiang B, Kennelly EJ, Kronenberg F, Kung AW: Ethanolic extract of Actaea racemosa (black cohosh) potentiates bone nodule formation in MC3T3-E1 preosteoblast cells. Bone 2008;43:567-573.
50. Rockwell S, Liu Y, Higgins SA: Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh. Breast Cancer Res Treat 2005;90:233-239.
51. Tsukamoto S, Aburatani M, Ohta T: Isolation of CYP3A4 inhibitors from the black cohosh (Cimicifuga racemosa). Evid Based Complement Alternat Med 2005;2:223-226.
52. Low Dog T, Powell KL, Weisman SM: Critical evaluation of the safety of Cimicifuga racemosa in menopause symptom relief. Menopause 2003;10:299-313.
53. Diaper A, Hindmarch I: A double-blind, placebo controlled investigation of the effects of two doses of a valerian preparation on the sleep, cognitive and psychomotor function of sleep-disturbed older adults. Phytother Res 2004;18:831-836.
54. Jacobs BP, Bent S, Tice JA, Blackwell T, Cummings SR: An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. Medicine (Baltimore). 2005;84:197-207.
55. Bent S, Padula A, Moore D, Patterson M, Mehling W: Valerian for sleep: A systematic review and meta-analysis. Am J Med Dec 2006;119:1005-1012.
56. Fernández-San-Martin MI, Masa-Font R, Palacios-Soler L, Sancho-Gómez P, Calbó-Caldentey C, Flores-Mateo G: Effectiveness of Valerian on insomnia: A meta-analysis of randomized placebo controlled trials. Sleep Med 2010;11:505-511.
57. Barton DL, Atherton PJ, Bauer BA, Moore DF Jr, Mattar BI, Lavasseur BI, et al.: The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: A phase III randomized, placebocontrolled, double-blind study (NCCTG Trial, N01C5). J Support Oncol 2011;9:24-31.
58. Plushner SL: Valerian: Valeriana officinalis. Am J Health Syst Pharm 2000;57:328,333,335.
59. Belch JJ, Hill A: Evening primrose oil and borage oil in rheumatologic conditions. Am J Clin Nutr 2000;71:S352-S356.
60. Tyler V: Herbs of Choice, the Therapeutical Use of Phytomedicinals. Binghamton, NY: Pharmaceutical Press, 1994.
61. Dove D, Johnson P: Oral evening primrose oil: Its effect on length of pregnancy and selected intrapartum outcomes in low-risk nulliparous women. J Nurse Midwifery 1999;44:320-324.
62. Wedig KE, Whitsett JA: Down the primrose path: Petechiae in a neonate exposed to herbal remedy for parturition. J Pediatr 2008;152(1):140,140e1.
63. DerMarderosian A: The Review of Natural Products. St. Louis, MO: Facts and Comparisons, 1999.
64. Bombardelli E, Morazzoni P: Vitis vinifera L. Fitoterapia 1995;66:291-317.
65. Ray SD, Patel D, Wong V, Bagchi D: In vivo protection of DNA damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract. Res Commun Mol Pathol Pharmacol 2000;107:137-166.
66. Yu H, Wang SE, Zhao C, Xu G: Study of anti-atherosclerosic effect of grape seed extract and its mechanism. Wei Sheng Yan Jiu 2002;31:263-265.
67. Bagchi D, Sen CK, Ray SD, Das DK, Bagchi M, Preuss HG, et al.: Molecular mechanisms of cardioprotection by a novel grape seed proanthocyanidin extract. Mutat Res 2003;523-524:87-97.
68. Preuss HG, Wallerstedt D, Talpur N, Tutuncuoglu SO, Echard B, Myers A, et al.: Effects of niacin bound chromium and grape seed proanthocyanidin extract on the lipid profile of hypercholesterolemic subjects: A pilot study. J Med 2000;31:227-246.
69. Nuttall SL, Kendall MJ, Bombardelli E, Morazzoni P: An evaluation of the antioxidant activity of a standardized grape seed extract, Leucoselect. J Clin Pharm Ther 1998; 23:385-389.
70. Olaku O, White JD: Herbal therapy use by cancer patients: A literature review on case reports. Eur J Cancer 2001; 47:508-514.
71. Fan S, Wang X: Herbal composition for treating prostate cancer: PC-SPES. U.S. Patent No. 08/697920. U.S. Patent and Trademark Office, 1997.
72. Weinrobe MC, Montgomery B: Acquired bleeding diathesis in a patient taking PC-SPES. N Engl J Med 2001;345:1213- 1214.
73. PC SPES For Prostate Health: Product Information. Brea, CA: BotanicLab, 2000.
74. DiPaola RS, Zhang H, Lambert GH, Meeker R, Licitra E, Rafi MM, et al.: Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 1998;339:785-791.
75. Pfeifer BL, Pirani JF, Hamann SR, Klippel KF: PCSPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. BJU Int 2000;85:481-485.
76. Small EJ, Frohlich MW, Bok R, Shinohara K, Grossfeld G, Rozenblat Z, et al.: Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 2000;18:3595-3603.
77. Bonham M, Arnold H, Montgomery B, Nelson PS: Molecular effects of the herbal compound PC-SPES: Identification of activity pathways in prostate carcinoma. Cancer Res 2002;62:3920-3924.
78. Bonham M, Posakony J, Coleman I, Montgomery B, Simon J, Nelson PS: Characterization of chemical constituents in Scutellaria baicalensis with antiandrogenic and growth-inhibitory activities toward prostate carcinoma. Clin Cancer Res 2005;11:3905-3914.
79. Sliva D: Ganoderma lucidum (Reishi) in cancer treatment. Integr Cancer Ther 2003;2:358-364.
80. Weng CJ, Yen GC: The in vitro and in vivo experimental evidences disclose the chemopreventive effects of Ganoderma lucidum on cancer invasion and metastasis. Exp Metastasis 2010;27:361-369.
81. Wang X, Zhao X, Li D, Lou YQ, Lin ZB, Zhang GL: Effects of Ganoderma lucidum polysaccharide on CYP2E1, CYP1A2 and CYP3A activities in BCG immune hepatic injury in rats. Biol Pharm Bull 2007;30:1702-1706.
82. Gill SK, Rieder MJ: Toxicity of a traditional Chinese medicine, Ganoderma lucidum, in children with cancer. Can J Clin Pharmacol 2008;15:e275-e285.
83. Manna SK, Sah NK, Newman RA, Cisneros A, Aggarwal BB: Oleandrin suppresses activation of nuclear transcription factor-kappaB, activator protein-1, and c-Jun NH2-terminal kinase. Cancer Res 2000;60:3838-3847.
84. Pathak S, Multani AS, Narayan S, Kumar V, Newman RA: Anvirzel, an extract of Nerium oleander, induces cell death in human but not murine cancer cells. Anticancer Drugs 2000;11:455-463.
85. Smith JA, Madden T, Vijjeswarapu M, Newman RA: Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell lines PC3 and DU145 by Anvirzel and its cardiac glycoside component, oleandrin. Biochem Pharmacol 2001;62:469-472.
86. Nasu S, Milas L, Kawabe S, Raju U, Newman R: Enhancement of radiotherapy by oleandrin is a caspase-3 dependent process. Cancer Lett 2002;185:145-151.
87. Mekhail T, Kaur H, Ganapathi R, Budd GT, Elson P, Bukowski RM: Phase 1 trial of Anvirzel in patients with refractory solid tumors. Invest New Drugs 2006;24: 423-427.
88. McConkey DJ, Lin Y, Nutt LK, Ozel HZ, Newman RA: Cardiac glycosides stimulate Ca2 + increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res 2000;60:3807-3812.
89. Sreenivasan Y, Raghavendra PB, Manna SK: Oleandrinmediated expression of Fas potentiates apoptosis in tumor cells. J Clin Immunol 2006;26:308-322.
90. Newman RA, Yang P, Hittelman WN, Lu T, Ho DH, Ni D, et al.: Oleandrin-mediated oxidative stress in human melanoma cells. J Exp Ther Oncol 2006;5:167-181.
91. Manna SK, Sreenivasan Y, Sarkar A: Cardiac glycoside inhibits IL-8-induced biological responses by downregulating IL-8 receptors through altering membrane fluidity. J Cell Physiol 2006;207:195-207.
92. Newman RA, Kondo Y, Yokoyama T, Dixon S, Cartwright C, Chan D, et al.: Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipid-soluble cardiac glycoside. Integr Cancer Ther 2007;6:354-364.
93. Ozel HZ, Ozel HZ, Ozel HZs: Extracts of Nerium species, methods of preparation, and use therefore. 1992. U.S. Patent No. 135:745. U.S. Patent and Trademark Office.
94. Schulz V, Rudolf H, Tyler VE: Rational Phytotherapy: A Physician's Guide to Herbal Medicine, 4th ed. New York: Springer, 2001.
95. Pae HO, Seo WG, Oh GS, Shin MK, Lee HS, Lee HS, et al.: Potentiation of tumor necrosis factoralpha-induced apoptosis by mistletoe lectin. Immunopharmacol Immunotoxicol 2000;22:697-709.
96. Schumacher U, Feldhaus S, Mengs U: Recombinant mistletoe lectin (rML) is successful in treating human ovarian cancer cells transplanted into severe combined immunodeficient (SCID) mice. Cancer Lett 2000;150:171-175.
97. Steuer-Vogt MK, Bonkowsky V, Ambrosch P, Scholz M, Neiss A, Strutz J, et al.: The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: A randomised controlled clinical trial. Eur J Cancer 2001;37:23-31.
98. Gutsch J, Berger H, Scholz G, Denck H: Prospektive Studie beim radikal operierten Mammakarzinom mit Polychemotherapie Helixor und unbehandelter Kontrolle. [German] Dtsch Zeitschrift Onkol 1988;4:94.
99. Kim KC, Yook JH, Eisenbraun J, Kim BS, Huber R: Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma: A randomized, controlled pilot study. BMC Complement Altern Med 2012;12:172.
100. Semiglazov VF, Stepula VV, Dudov A, SchnitkerJ, Mengs U: Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: A randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res 2006;26:1519-1529.
101. Lenartz D, Dott U, Menzel J, Schierholz JM, Beuth J: Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 2000;20:2073-2076.
102. Kleeberg UR, Suciu S, Bröcker EB, Ruiter DJ, Chartier C, Liénard D, et al.: Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-alpha2b versus rIFNgamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness > 3mm) or regional lymph node metastasis. Eur J Cancer 2004;40:390-402.
103. Ernst E, Schmidt K, Steuer-Vogt MK: Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer 2003;107:262-267.
104. Kienle GS, Kiene H: Complementary cancer therapy: A systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res 2007;12:103.
105. Ostermann T, Raak C, Büssing A: Survival of cancer patients treated with mistletoe extract (Iscador): A systematic literature review. BMC Cancer 2009;9:451.
106. Stein GM, Berg PA: Adverse effects during therapy with mistletoe extracts. In: Büssig A (ed): Mistletoe: The Genus Viscum. Amsterdam: Hardwood Academic Publishers, 2000, p.195.
107. Kleijnen J, Knipschild P: Mistletoe treatment for cancer: Review of controlled trials in humans. Phytomedicine 1994;1:255-260.
108. Grossarth-Maticek R, Kiene H, Baumgartner SM, Ziegler R: Use of Iscador, an extract of European mistletoe (Viscum album) in cancer treatment: Prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med 2001;7: 57-78.
109. Grossarth-Maticek R, Ziegler R: Randomised and nonrandomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): A reanalysis. Eur J Med Res 2006;11:485-495.
110. Gorter RW, van Wely M, Stoss M, Wollina U: Subcutaneous infiltrates induced by injection of mistletoe extracts (Iscador). Am J Ther 1998;5:181-187.
111. Schulz V: Rational Phytotherapy: A Physician's Guide to Herbal Medicine, 4th ed. New York: Springer, 2001.
112. Bussing A, Stumpf C, Troger W, Schietzel M: Course of mitogen-stimulated T lymphocytes in cancer patients treated with Viscum album extracts. Anticancer Res 2007;27: 2903-2910.
113. Newall CA: Herbal Medicines: A Guide for Health Care Professionals. London: Pharmaceutical Press, 1996.
114. Chiu J, Yau T, Epstein RJ: Complications of traditional Chinese/herbal medicines(TCM): A guide for perplexed oncologists and other cancer caregivers. Support Care Cancer 2009;17:231-240.
115. Madisch A, Holtmann G, Mayr G, Vinson B, Hotz J: Treatment of functional dyspepsia with a herbal preparation: A double-blind, randomized, placebo controlled, multicenter trial. Digestion 2004;69:45-52.
116. Gupta VK, Fatima A, Faridi U, Negi AS, Shanker K, Kumar JK, et al.: Antimicrobial potential of Glycyrrhiza glabra roots. J Ethnopharmacol 2008;116:377-380.
117. Jo EH, Hong HD, Ahn NC, Jung JW, Yang SR, Park JS, et al.: Modulations of the Bcl-2/Bax family were involved in the chemopreventive effects of licorice root (Glycyrrhiza uralensis Fisch) in MCF-7 human breast cancer cell. J Agric Food Chem 2004;52:1715-1719.
118. Takahashi T, Takasuka N, Iigo M, Baba M, Nishino H, Tsuda H, et al.: Isoliquiritigenin, a flavonoid from licorice, reduces prostaglandin E2 and nitric oxide, causes apoptosis, and suppresses aberrant crypt foci development. Cancer Sci 2004;95:448-453.
119. De Smet PAGM: Adverse Effects of Herbal Drugs, Vol.3. New York: Springer, 1997.
120. Lin SH, Yang SS, Chau T, Halperin ML: An unusual cause of hypokalemic paralysis: Chronic licorice ingestion. Am J Med Sci 2003;325:153-156.
121. Brinker F: Herb Contraindications and Drug Interactions, 2nd ed. Sandy, OR: Eclectic Medical Publications, 1998.
122. Newall CA, Anderson LA, Phillipson JD: Herbal Medicines: A Guide for Health-Care Professionals, 1st ed. London: Pharmaceutical Press, 1996.
123. Somjen D, Knoll E, Vaya J, Stern N, Tamir S: Estrogen-like activity of licorice root constituents: Glabridin and glabrene, in vascular tissues in vitroand in vivo. J Steroid Biochem Mol Biol 2004;91:147-155.
124. Breidthardt T, Namdar M, Hess B: A hypertensive urgency induced by the continuous intake of a herbal remedy containing liquorice. J Hum Hypertens 2006;20:465-466.
125. Chandrasekaran CV, Deepak HB, Thiyagarajan P, et al.: Dual inhibitory effect of Glycyrrhiza glabra (GutGard) on COX and LOX products. Phytomedicine 2010;21.
126. Tu JH, He YJ, Chen Y, Fan L, Zhang W, Tan ZR, et al.: Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur J Clin Pharmacol 2010;66:805-810.
127. McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, et al.: Astragalus-based Chinese herbs and platinumbased chemotherapy for advanced non-small-cell lung cancer: Meta-analysis of randomized trials. J Clin Oncol 2006;24:419-430.
128. Chu DT, Wong WL, Mavligit GM: Immunotherapy with Chinese medicinal herbs: II. Reversal of cyclophosphamideinduced immune suppression by administration of fractionated Astragalus membranaceus in vivo. J Clin Lab Immunol 1988;25:125-129.
129. Chu DT, Lepe-Zuniga J, Wong WL, LaPushin R, Mavligit GM: Fractionated extract of Astragalus, a Chinese medicinal herb, potentiates LAK cell cytotoxicity generated by a low dose of recombinant interleukin-2. J Clin Lab Immunol 1988;26:183-187.
130. Upton R: Astragalus root: Analytical, quality control and therapeutic monograph. In: American Herbal Pharmacopoeia. Scotts Valley, CA: American Herbal Pharmacopoeia, 1999, pp. 1-25.
131. Newall CA: Herbal Medicines: A Guide for Health-Care Professional. London: Pharmaceutical Press, 1996.
132. Hickok JT, Roscoe JA, Morrow GR, Ryan JL: A phase II/III randomized, placebo-controlled, double-blind clinical trial of ginger (Zingiber officinale) for nausea caused by chemotherapy for cancer: A currently accruing URCC CCOP cancer control study. Current Trial 2007;4(4):247-250.
133. Somasundaram S, Edmund NA, Moore DT, Small GW, Shi YY, Orlowski RZ: Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res 2002;62:3868-3875.
134. Shaw D: Toxicological risks of Chinese herbs. Planta Med 2010;76:2012-2018.
135. Yildiz I, Ozguroglu M, Toptas T, Turna H, Sen F, Yildiz M: Patterns of complementary and alternative medicine use among Turkish cancer patients. J Palliat Med 2013;16:383-390.
136. Bent S, Ko R: Commonly used herbal medicines in the United States: A review. Am J Med 2004;116:478-485.
137. Chan KK, Yao TJ, Jones B, Zhao JF, Ma FK, Leung CY, et al.: The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: A double-blind placebo-controlled randomized trial with immunological monitoring. Ann Oncol 2011;22:2241-2249.
138. Mok TS, Yeo W, Johnson PJ, Hui P, Ho WM, Lam KC, et al.: A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Ann Oncol 2007;18:768-774.
139. Guo R, Canter PH, Ernst E: A systematic review of randomised clinical trials of individualised herbal medicine in any indication. Postgrad Med J 2007;83:633-637.
140. Ma H, Carpenter CL, Sullivan-Halley J, Bernstein L: The roles of herbal remedies in survival and quality of life among long-term breast cancer survivors: Results of a prospective study. BMC Cancer 2011;11:222.